Literature DB >> 19116992

Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer.

Fredrik Wiklund1, S Lilly Zheng, Jielin Sun, Hans-Olov Adami, Hans Lilja, Fang-Chi Hsu, Pär Stattin, Jan Adolfsson, Scott D Cramer, David Duggan, John D Carpten, Bao-Li Chang, William B Isaacs, Henrik Grönberg, Jianfeng Xu.   

Abstract

BACKGROUND: Prostate specific antigen (PSA) is widely used for prostate cancer screening but its levels are influenced by many non cancer-related factors. The goal of the study is to estimate the effect of genetic variants on PSA levels.
METHODS: We evaluated the association of SNPs that were reported to be associated with prostate cancer risk in recent genome-wide association studies with plasma PSA levels in a Swedish study population, including 1,722 control subjects without a diagnosis of prostate cancer.
RESULTS: Of the 16 SNPs analyzed in control subjects, significant associations with PSA levels (P < or = 0.05) were found for six SNPs. These six SNPs had a cumulative effect on PSA levels; the mean PSA levels in men were almost twofold increased across increasing quintile of number of PSA associated alleles, P-trend = 3.4 x 10(-14). In this Swedish study population risk allele frequencies were similar among T1c case patients (cancer detected by elevated PSA levels alone) as compared to T2 and above prostate cancer case patients.
CONCLUSIONS: Results from this study may have two important clinical implications. The cumulative effect of six SNPs on PSA levels suggests genetic-specific PSA cutoff values may be used to improve the discriminatory performance of this test for prostate cancer; and the dual associations of these SNPs with PSA levels and prostate cancer risk raise a concern that some of reported prostate cancer risk-associated SNPs may be confounded by the prevalent use of PSA screening. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19116992      PMCID: PMC3348520          DOI: 10.1002/pros.20908

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  35 in total

1.  Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci.

Authors:  W Xue; R A Irvine; M C Yu; R K Ross; G A Coetzee; S A Ingles
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

2.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

3.  Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms.

Authors:  Anuradha Rao; Bao-L i Chang; Gregory Hawkins; Jennifer J Hu; Charles J Rosser; M Craig Hall; Deborah A Meyers; Jianfeng Xu; Scott D Cramer
Journal:  Urology       Date:  2003-04       Impact factor: 2.649

4.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.

Authors:  H Lilja
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

5.  Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk.

Authors:  Andrea Gsur; Martin Preyer; Gerald Haidinger; Thomas Zidek; Stephan Madersbacher; Georg Schatzl; Michael Marberger; Christian Vutuc; Michael Micksche
Journal:  Carcinogenesis       Date:  2002-10       Impact factor: 4.944

6.  Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.

Authors:  Scott D Cramer; Bao-Li Chang; Anuradha Rao; Gregory A Hawkins; S Lilly Zheng; Wendy N Wade; Roger T Cooke; Leanne N Thomas; Eugene R Bleecker; William J Catalona; David A Sterling; Deborah A Meyers; Jill Ohar; Jianfeng Xu
Journal:  J Natl Cancer Inst       Date:  2003-07-16       Impact factor: 13.506

7.  Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.

Authors:  C Sävblom; A Giwercman; J Malm; C Halldén; K Lundin; H Lilja; Y Giwercman
Journal:  Int J Androl       Date:  2008-03-10

8.  Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.

Authors:  Rui Medeiros; Antonio Morais; André Vasconcelos; Sandra Costa; Daniela Pinto; Jorge Oliveira; Rodrigo Carvalho; Carlos Lopes
Journal:  Prostate       Date:  2002-09-15       Impact factor: 4.104

9.  Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population.

Authors:  Li-Zhong Wang; Kazunari Sato; Norihiko Tsuchiya; Jian-Gang Yu; Chikara Ohyama; Shigeru Satoh; Tomonori Habuchi; Osamu Ogawa; Tetsuro Kato
Journal:  Cancer Lett       Date:  2003-12-08       Impact factor: 8.679

10.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease.

Authors:  P Cohen; D M Peehl; H C Graves; R G Rosenfeld
Journal:  J Endocrinol       Date:  1994-09       Impact factor: 4.286

View more
  22 in total

1.  Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Authors:  Sarah M Troutman; Tristan M Sissung; Cheryl D Cropp; David J Venzon; Shawn D Spencer; Bamidele A Adesunloye; Xuan Huang; Fatima H Karzai; Douglas K Price; William D Figg
Journal:  Oncologist       Date:  2012-03-01

2.  Utility of genome-wide association study findings: prostate cancer as a translational research paradigm.

Authors:  A R Turner; A K Kader; J Xu
Journal:  J Intern Med       Date:  2012-04       Impact factor: 8.989

3.  Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history.

Authors:  Fang-Chi Hsu; Jielin Sun; Yi Zhu; Seong-Tae Kim; Tao Jin; Zheng Zhang; Fredrik Wiklund; A Karim Kader; S Lilly Zheng; William Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-23       Impact factor: 4.254

4.  Estimation of absolute risk for prostate cancer using genetic markers and family history.

Authors:  Jianfeng Xu; Jielin Sun; A Karim Kader; Sara Lindström; Fredrik Wiklund; Fang-Chi Hsu; Jan-Erik Johansson; S Lilly Zheng; Gilles Thomas; Richard B Hayes; Peter Kraft; David J Hunter; Stephen J Chanock; William B Isaacs; Henrik Grönberg
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

5.  Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

Authors:  Danyelle A Winchester; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Jianfeng Xu; S Lilly Zheng; Ian M Thompson; M Scott Lucia; Scott M Lippmann; Howard L Parnes; Paul J Dluzniewski; William B Isaacs; Angelo M De Marzo; Charles G Drake; Elizabeth A Platz
Journal:  Prostate       Date:  2015-06-05       Impact factor: 4.104

6.  Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.

Authors:  Jiyoung Ahn; Adam S Kibel; Jong Y Park; Timothy R Rebbeck; Hanna Rennert; Janet L Stanford; Elaine A Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D Mittal; William B Isaacs; Elizabeth A Platz; Richard B Hayes
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

7.  Genetic correction of PSA values using sequence variants associated with PSA levels.

Authors:  Julius Gudmundsson; Soren Besenbacher; Patrick Sulem; Daniel F Gudbjartsson; Isleifur Olafsson; Sturla Arinbjarnarson; Bjarni A Agnarsson; Kristrun R Benediktsdottir; Helgi J Isaksson; Jelena P Kostic; Sigurjon A Gudjonsson; Simon N Stacey; Arnaldur Gylfason; Asgeir Sigurdsson; Hilma Holm; Unnur S Bjornsdottir; Gudmundur I Eyjolfsson; Sebastian Navarrete; Fernando Fuertes; Maria D Garcia-Prats; Eduardo Polo; Ionel A Checherita; Mariana Jinga; Paula Badea; Katja K Aben; Jack A Schalken; Inge M van Oort; Fred C Sweep; Brian T Helfand; Michael Davis; Jenny L Donovan; Freddie C Hamdy; Kristleifur Kristjansson; Jeffrey R Gulcher; Gisli Masson; Augustine Kong; William J Catalona; Jose I Mayordomo; Gudmundur Geirsson; Gudmundur V Einarsson; Rosa B Barkardottir; Eirikur Jonsson; Viorel Jinga; Dana Mates; Lambertus A Kiemeney; David E Neal; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Sci Transl Med       Date:  2010-12-15       Impact factor: 17.956

8.  Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels.

Authors:  Kathryn L Penney; Fredrick R Schumacher; Peter Kraft; Lorelei A Mucci; Howard D Sesso; Jing Ma; Yuxin Niu; Jit Kong Cheong; David J Hunter; Meir J Stampfer; Stephen I Hsu
Journal:  Carcinogenesis       Date:  2011-03-18       Impact factor: 4.944

Review 9.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

10.  Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.

Authors:  Danyelle A Winchester; Bora Gurel; Cathee Till; Phyllis J Goodman; Catherine M Tangen; Regina M Santella; Teresa L Johnson-Pais; Robin J Leach; Ian M Thompson; Jianfeng Xu; S Lilly Zheng; M Scott Lucia; Scott M Lippman; Howard L Parnes; William B Isaacs; Charles G Drake; Angelo M De Marzo; Elizabeth A Platz
Journal:  Prostate       Date:  2016-01-15       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.